SEC Form 4 · accession 0001638599-16-001415
Fortress Biotech, Inc. · FBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Avgerinos
Officer — SVP, Biologics Operations
Period of report
Sep 15, 2016
Accepted (ET)
Sep 19, 2016 · 4:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001429260
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001F1 | Sep 15, 2016 | S | 15,000 | $2.54 | D | 293,000 | D | |
| Common Stock, par value $0.001F2 | Sep 16, 2016 | S | 33,912 | $2.55 | D | 259,088 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades ranging from $2.49 to $2.58. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- F2This transaction was executed in multiple trades ranging from $2.53 to $2.62. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.